(6-Methylpyridazin-3-yl)methanamine dihydrochloride | 1630907-25-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (6-Methylpyridazin-3-yl)methanamine dihydrochloride
• 英文别名: (6-methylpyridazin-3-yl)methanamine;dihydrochloride
• CAS: 1630907-25-3
• 化学式: C6H11Cl2N3
• 分子量: 196.07
• InChiKey: DHHBGVAVHZOVNW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.09
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  51.8
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• [EN] PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIDOPYRIMIDINES UTILISÉS EN TANT QU'INHIBITEURS DE P2X3
  申请人：CHIESI FARM SPA

  公开号：WO2020239953A1

  公开（公告）日：2020-12-03

  The present invention relates to compounds of formula I inhibiting P2X purinoceptor 3 (hereinafter P2X3 inhibitors); particularly the invention relates to compounds that are pyridopyrimidines derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).

  本发明涉及公式I的化合物，抑制P2X嘌呤受体3（以下简称P2X3抑制剂）；特别是涉及吡啶嘧啶衍生物化合物，制备这种化合物的方法，含有它们的药物组合物以及它们的治疗用途。本发明的化合物可能在治疗许多与P2X3受体机制相关的疾病中有用，如呼吸道疾病，包括咳嗽、哮喘、特发性肺纤维化（IPF）和慢性阻塞性肺病（COPD）。
• [EN] (AZA)QUINOLINE 4-AMINES DERIVATIVES AS P2X3 INHIBITORS<br/>[FR] DÉRIVÉS DE (AZA)QUINOLÉINE 4-AMINES SERVANT D'INHIBITEURS DE P2X3
  申请人：CHIESI FARM SPA

  公开号：WO2022112491A1

  公开（公告）日：2022-06-02

  The present invention relates to compounds of formula (I) inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are (aza)quinoline 4-amines derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X3receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).

  本发明涉及公式（I）的化合物，该化合物抑制P2X嘌呤受体3；特别是涉及（氮杂）喹啉4-胺衍生物的化合物，制备这种化合物的方法，含有它们的制药组合物以及其治疗用途。本发明的化合物可能在治疗许多与P2X3受体机制相关的疾病中有用，例如呼吸道疾病，包括咳嗽，哮喘，特发性肺纤维化（IPF）和慢性阻塞性肺疾病（COPD）。
• PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS
  申请人：CHIESI FARMACEUTICI S.p.A.

  公开号：US20220235060A1

  公开（公告）日：2022-07-28

  The present invention relates to compounds of formula I inhibiting P2X purinoceptor 3 (hereinafter P2X 3 inhibitors); particularly the invention relates to compounds that are pyridopyrimidines derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X 3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).
• AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS
  申请人：CHIESI FARMACEUTICI S.p.A.

  公开号：US20220227749A1

  公开（公告）日：2022-07-21

  The present invention relates to compounds of formula I inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are amino quinazoline derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X 3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).